Fact CheckerSign in

NCT05039216Recruiting

Biobank for Inflammatory Chronic Diseases and Osteoporosis

Biobank for Inflammatory Chronic Diseases and Osteoporosis of TOULouse

Source: ClinicalTrials.gov · Last updated 19 Mar 2026

Brief summary (registry, in English)

The aim of this study is to constitute a biobank for patients followed in the Rheumatology center of Toulouse University Hospital for a chronic inflammatory rheumatism including rheumatoid arthritis (RA), spondyloarthritis(SpA), and psoriatic arthritis (PsA) or a chronic bone disease including osteoporosis in order to identify biomarkers associated with therapeutic response.

Status (registry)
Recruiting
Study type
Observational
Enrollment
2000 (estimated)
First submitted
6 Sept 2021
Start date
Sept 2021
Primary completion date
Sept 2026
Lead sponsor
University Hospital, Toulouse
NCT number
NCT05039216

What you commit to

  • Study type: Observational
  • Planned participants: 2000
  • From Sept 2021 to the primary completion date, Sept 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Pregnancy or breastfeeding
  • Not able to give a consent
  • Severe anemia (Hb\<10g/L)

Who the study is looking for

  • Chronic inflammatory rheumatism including RA, SpA or PsA or patients with primary or secondary osteoporosis
  • With National Health Assurance
  • Able to consent to the study

Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Purpan University Hospital
Coordinator of this site? Confirm its status
ToulouseFranceRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.